T. Rowe Price Associates
CTMX icon

T. Rowe Price Associates’s CytomX Therapeutics CTMX Stock Holding History

T. Rowe Price Associates’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-633,418
Closed -$1.16M – 2969
2022
Q2 		$1.16M Sell
633,418
-27,645
-4% -$52.9K ﹤0.01% 1826
2022
Q1 		$1.76M Buy
661,063
+1,200
+0.2% +$4.61K ﹤0.01% 1736
2021
Q4 		$2.86M Sell
659,863
-2,802
-0.4% -$16.4K ﹤0.01% 1600
2021
Q3 		$3.37M Sell
662,665
-25,659
-4% -$137K ﹤0.01% 1577
2021
Q2 		$4.36M Sell
688,324
-1,007,942
-59% -$7.85M ﹤0.01% 1530
2021
Q1 		$13.1M Buy
1,696,266
+1,009,792
+147% +$7.99M ﹤0.01% 1351
2020
Q4 		$4.5M Sell
686,474
-200
-0% -$1.43K ﹤0.01% 1457
2020
Q3 		$4.57M Hold
686,674
– – ﹤0.01% 1413
2020
Q2 		$5.72M Buy
686,674
+276
+0% +$2.56K ﹤0.01% 1371
2020
Q1 		$5.26M Buy
686,398
+210
+0% +$1.46K ﹤0.01% 1333
2019
Q4 		$5.7M Sell
686,188
-1,518,913
-69% -$10.2M ﹤0.01% 1379
2019
Q3 		$16.3M Sell
2,205,101
-595,771
-21% -$5.88M ﹤0.01% 1209
2019
Q2 		$31.4M Sell
2,800,872
-289,801
-9% -$3.04M ﹤0.01% 1031
2019
Q1 		$33.2M Sell
3,090,673
-1,000,853
-24% -$14.8M ﹤0.01% 1017
2018
Q4 		$61.8M Buy
4,091,526
+3,923
+0.1% +$58.2K 0.01% 744
2018
Q3 		$75.6M Buy
4,087,603
+838,139
+26% +$19.1M 0.01% 765
2018
Q2 		$74.3M Buy
3,249,464
+377,032
+13% +$9.63M 0.01% 751
2018
Q1 		$81.7M Buy
2,872,432
+2,442,345
+568% +$69.7M 0.01% 699
2017
Q4 		$9.08M Buy
430,087
+120,004
+39% +$2.49M ﹤0.01% 1356
2017
Q3 		$5.63M Buy
310,083
+67,393
+28% +$1.05M ﹤0.01% 1422
2017
Q2 		$3.76M Buy
242,690
+94,385
+64% +$1.42M ﹤0.01% 1450
2017
Q1 		$2.56M Sell
148,305
-52,898
-26% -$696K ﹤0.01% 1522
2016
Q4 		$2.21M Buy
+201,203
New +$2.44M ﹤0.01% 1535
2016
Q3 		– Sell
-15,000
Closed -$153K – 2535
2016
Q2 		$153K Buy
+15,000
New +$171K ﹤0.01% 2372

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

T. Rowe Price Associates's CTMX Position: Q3 2022 in Review

T. Rowe Price Associates sold out of CytomX Therapeutics (CTMX) in Q3 2022, closing a stake of 633,418 shares — an estimated $1.16M sold.

T. Rowe Price Associates first reported a position in CTMX in Q2 2016 and held it in 24 quarters. The position peaked at $81.7M in Q1 2018. 84 funds tracked by Wall St. Rank hold CTMX as of Q3 2022.

  • T. Rowe Price Associates reported no remaining CytomX Therapeutics position as of Q3 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 633,418 CytomX Therapeutics shares in Q3 2022, an estimated $1.16M.
  • T. Rowe Price Associates first reported a position in CytomX Therapeutics in Q2 2016 and held it in 24 quarters.
  • T. Rowe Price Associates's CytomX Therapeutics position peaked at $81.7M in Q1 2018.
  • 84 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.